A USC-licensed startup that developed an intranasal drug delivery system for brain tumors will be listed for the first time on Nasdaq on Wednesday. To celebrate the direct listing, the USC Stevens Center for Innovation and the startup, NeOnc Technologies Holdings Inc., will ring the opening bell at 9:30 a.m. EDT/6:30 a.m. PDT.

NeOnc is based on intellectual property developed by neurosurgeon and NeOnc founder Thomas Chen, MD, PhD, of Keck Medicine of USC, who is also a tenured professor of neurological surgery and pathology with the Keck School of Medicine of USC. NeOnc is the first USC-licensed biotech company with agreements through USC Stevens to go public.

To continue reading, click here.